Literature DB >> 20856701

Refocusing the debate: evidence-based clinical cancer research versus marketplace reality.

Maurie Markman.   

Abstract

The continued development and licensing of modestly beneficial high-priced treatments, and the potential for widening disparities in cancer care, warrant a renewed focus on how we measure and define benefits and cost.

Entities:  

Year:  2008        PMID： 20856701      PMCID： PMC2794021          DOI： 10.1200/JOP.0858505

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  2 in total

1.  The price tag on progress--chemotherapy for colorectal cancer.

Authors:  Deborah Schrag
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

2.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245
  2 in total
  1 in total

1.  Let's Focus on Value.

Authors:  Neal J Meropol
Journal:  J Oncol Pract       Date:  2008-09       Impact factor: 3.840
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.